<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Transgene Sa — News on 6ix</title>
    <link>https://6ix.com/company/transgene-sa</link>
    <description>Latest news and press releases for Transgene Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 09 Apr 2026 16:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/transgene-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836198378dffbe2df13e65a.webp</url>
      <title>Transgene Sa</title>
      <link>https://6ix.com/company/transgene-sa</link>
    </image>
    <item>
      <title>Availability of Transgene’s  2025 Universal Registration Document (URD)</title>
      <link>https://6ix.com/company/transgene-sa/news/availability-of-transgenes-2025-universal-registration-document-urd</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/availability-of-transgenes-2025-universal-registration-document-urd</guid>
      <pubDate>Thu, 09 Apr 2026 16:00:00 GMT</pubDate>
      <description>Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241. This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF forma</description>
    </item>
    <item>
      <title>Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-and-nec-bio-sign-license-agreement-to-prepare-the-next-steps-of-the-development-of-tg4050-in-head-and-neck-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-and-nec-bio-sign-license-agreement-to-prepare-the-next-steps-of-the-development-of-tg4050-in-head-and-neck-cancer</guid>
      <pubDate>Thu, 02 Apr 2026 15:45:00 GMT</pubDate>
      <description>Strasbourg, France &amp; Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant</description>
    </item>
    <item>
      <title>Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-to-deliver-an-oral-presentation-on-its-individualized-neoantigen-therapeutic-vaccine-tg4050-at-the-world-vaccine-congress</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-to-deliver-an-oral-presentation-on-its-individualized-neoantigen-therapeutic-vaccine-tg4050-at-the-world-vaccine-congress</guid>
      <pubDate>Thu, 26 Mar 2026 16:45:00 GMT</pubDate>
      <description>Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1st. The presentation will highlight findin</description>
    </item>
    <item>
      <title>Transgene Announces Financial Calendar for 2026</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-announces-financial-calendar-2026-164500027</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-announces-financial-calendar-2026-164500027</guid>
      <pubDate>Wed, 04 Feb 2026 16:45:00 GMT</pubDate>
      <description>Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: Third Quarter 2</description>
    </item>
    <item>
      <title>Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-further-strengthens-scientific-advisory-070000906</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-further-strengthens-scientific-advisory-070000906</guid>
      <pubDate>Fri, 23 Jan 2026 07:00:00 GMT</pubDate>
      <description>Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership. “Antoine and Ignacio are world leaders in precision medicine, immune-oncology and cancer immu</description>
    </item>
    <item>
      <title>Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2025</title>
      <link>https://6ix.com/company/transgene-sa/news/balance-sheet-liquidity-contract-natixis-170000451</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/balance-sheet-liquidity-contract-natixis-170000451</guid>
      <pubDate>Mon, 12 Jan 2026 17:00:00 GMT</pubDate>
      <description>Strasbourg, January 12, 2026 – 06:00 p.m. CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2025, the following resources were managed through the liquidity account: 304,479 shares€ 147,574.00 In the second half of 2025, a total of: Purchases348,958 shares€ 389,221.00988 market transactionsSales372,229 shares€ 424,419.001,278 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resour</description>
    </item>
    <item>
      <title>Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-publishes-phase-data-supporting-070000799</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-publishes-phase-data-supporting-070000799</guid>
      <pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
      <description>TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehensive analysis of both the clinical and translation</description>
    </item>
    <item>
      <title>Transgene to Participate in Upcoming Investor Meetings</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-participate-upcoming-investor-meetings-164500878</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-participate-upcoming-investor-meetings-164500878</guid>
      <pubDate>Wed, 17 Dec 2025 16:45:00 GMT</pubDate>
      <description>Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: LifeSci Partners Corporate Access Event (by LifeSci Partners), on January 12 and 13, 2026, in San Francisco (United States) in conjunction with the JP Morgan Healthcare Conference;Biomed Forum (by Alli</description>
    </item>
    <item>
      <title>Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-announces-resume-trading-shares-231500555</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-announces-resume-trading-shares-231500555</guid>
      <pubDate>Wed, 26 Nov 2025 23:15:00 GMT</pubDate>
      <description>Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday, 26 November 2025, before market opening, pending the publication of the results of its capital increase. Following the announcement of the results of its capital increase on 26 November 2025, trading of its shares on Euronext Paris will resume on Thursday, 27 November 2025, at market opening. *** Con</description>
    </item>
    <item>
      <title>Transgene Successfully Completes a Fundraising  of c. €105 Million</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-successfully-completes-fundraising-c-223300188</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-successfully-completes-fundraising-c-223300188</guid>
      <pubDate>Wed, 26 Nov 2025 22:33:00 GMT</pubDate>
      <description>This press release may not be distributed directly or indirectly in the United States, Canada, United Kingdom, Australia or Japan. Success of a fundraising consisting of a reserved offering to local and international institutional investors via a private placement through an accelerated book building, and a public offering, intended for retail investors via the PrimaryBid platform, at a price of € 1.02 per share for a total amount of c. €105 million The funds raised will enable the acceleration</description>
    </item>
    <item>
      <title>Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris</title>
      <link>https://6ix.com/company/transgene-sa/news/correction-transgene-announces-temporary-suspension-204300132</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/correction-transgene-announces-temporary-suspension-204300132</guid>
      <pubDate>Tue, 25 Nov 2025 20:43:00 GMT</pubDate>
      <description>Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase. Trading on Euronext Paris is expected to resume on Thursday, November 27, 2025, at the opening of the markets. *** Contacts Transgene: Media:Investors &amp; Analysts:Caroline ToschLucie LarguierCorporate and S</description>
    </item>
    <item>
      <title>Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-announces-temporary-suspension-trading-194200952</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-announces-temporary-suspension-trading-194200952</guid>
      <pubDate>Tue, 25 Nov 2025 19:42:00 GMT</pubDate>
      <description>Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase. Trading on Euronext Paris is expected to resume on Thursday, November 27, 2025, at the opening of the markets. *** Contacts Transgene: Media:Investors &amp; Analysts:Caroline ToschLucie LarguierCorporate and S</description>
    </item>
    <item>
      <title>Correction: Transgene launches a fundraising campaign for approximately 105 million euros</title>
      <link>https://6ix.com/company/transgene-sa/news/correction-transgene-launches-fundraising-campaign-191000100</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/correction-transgene-launches-fundraising-campaign-191000100</guid>
      <pubDate>Tue, 25 Nov 2025 19:10:00 GMT</pubDate>
      <description>This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan. Cancels and replaces the 7:00 p.m. version – Correction in the dilution tables Fundraising consisting of a reserved offering to international institutional investors via a Private Placement through an accelerated book building, and a public offering, intended for retail investors via the PrimaryBid platform Institut Mérieux (TSGH) to participate for a minimum am</description>
    </item>
    <item>
      <title>Transgene launches a fundraising campaign for approximately 105 million euros</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-launches-fundraising-campaign-approximately-181600137</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-launches-fundraising-campaign-approximately-181600137</guid>
      <pubDate>Tue, 25 Nov 2025 18:16:00 GMT</pubDate>
      <description>This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan. Fundraising consisting of a reserved offering to international institutional investors via a Private Placement through an accelerated book building, and a public offering, intended for retail investors via the PrimaryBid platform Institut Mérieux (TSGH) to participate for a minimum amount of €70 million and intention of two other existing shareholders including</description>
    </item>
    <item>
      <title>Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-showcase-potential-proprietary-vacdesignr-073000712</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-showcase-potential-proprietary-vacdesignr-073000712</guid>
      <pubDate>Thu, 06 Nov 2025 07:30:00 GMT</pubDate>
      <description>Computational tool improves recombinant virus design efficiency and yield. This innovative in-house development is a key component of Transgene’s INTV1 platform. Poster to be presented at ESMO-AI 2025 Strasbourg, France, November 6, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announced it will present a poster on its proprietary VacDesignR® computational tool at the upcoming ESMO</description>
    </item>
    <item>
      <title>Transgene Provides Business and Financial Update for Q3 2025</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-provides-business-financial-q3-165000832</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-provides-business-financial-q3-165000832</guid>
      <pubDate>Tue, 04 Nov 2025 16:50:00 GMT</pubDate>
      <description>Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC) patients, to be presented at SITC 2025 New TG4050 data further validate its mechanism of action and potential to reduce risk of relapse presented at ASCO 2025 First immunogenicity data in the ongoing Phase II trial in operable HNSCC expected in H2 2026 Strasbourg, France, November 4, 2025, 5:50 p.m. CET – Tra</description>
    </item>
    <item>
      <title>New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse</title>
      <link>https://6ix.com/company/transgene-sa/news/phase-immunological-data-presented-sitc-164500731</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/phase-immunological-data-presented-sitc-164500731</guid>
      <pubDate>Tue, 04 Nov 2025 16:45:00 GMT</pubDate>
      <description>New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s ability to induce neoantigen-specific cytotoxic CD8+ T cell responses capable of targeting and eliminating tumor cells, supporting its potential to reduce risk of relapse Conference call scheduled on November 14 at 4 p.m. CET (in English). See details below. Strasbourg, France &amp; Tokyo, Japan, November 4,</description>
    </item>
    <item>
      <title>Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-present-immunological-data-phase-154500282</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-present-immunological-data-phase-154500282</guid>
      <pubDate>Fri, 03 Oct 2025 15:45:00 GMT</pubDate>
      <description>Strasbourg, France, October 3, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will take place November 5 to 9, 2025, in</description>
    </item>
    <item>
      <title>Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data   Randomization to be Completed in Phase II Part in Q4 2025</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-individualized-neoantigen-therapeutic-cancer-154500414</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-individualized-neoantigen-therapeutic-cancer-154500414</guid>
      <pubDate>Tue, 16 Sep 2025 15:45:00 GMT</pubDate>
      <description>2025 Half-Year Results and Business Update Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025) Transgene to report additional immunological data at a scientific conference in Q4 2025 Ongoing Phase II part with TG4050 in operable HNSCC Patient screening completed, completion of randomization expected in Q4 2025First immunogenicity data exp</description>
    </item>
    <item>
      <title>Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director</title>
      <link>https://6ix.com/company/transgene-sa/news/transgene-appoints-seasoned-industry-executive-154500954</link>
      <guid isPermaLink="true">https://6ix.com/company/transgene-sa/news/transgene-appoints-seasoned-industry-executive-154500954</guid>
      <pubDate>Wed, 09 Jul 2025 15:45:00 GMT</pubDate>
      <description>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors. She succeeds Philippe Archinard, who is retiring from the Board. Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recentl</description>
    </item>
  </channel>
</rss>